Curis Lifesciences
CURIS NSE
Curis Lifesciences
HealthcareNSE: CURIS Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹160 Cr
P/E Ratio
24.4
EBITDA
₹11.12 Cr
Return on Equity
37.62%
Debt to Equity
0.46
Book Value
₹58.57
52W High
₹228.8
52W Low
₹83.6
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 39.0%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 123 days to 232 days
Growth Rate
Revenue Growth
22.24% higher than
3Y
Net Income Growth
13.61% lower than
3Y
Cash Flow Change
-729% lower than
3Y
ROE
-60.11% lower than
3Y
ROCE
-29.27% lower than
3Y
EBITDA Margin (Avg.)
-9.78% higher than
3Y
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 15.9 | 34.36 | 27.91 | 32.72 |
| Expenses | 12.09 | 27.43 | 21.92 | 27.58 |
| Operating Profit | 3.81 | 6.93 | 5.99 | 5.14 |
| OPM % | 23.96% | 20.17% | 21.46% | 15.71% |
| Other Income | -0.02 | 0.05 | 0 | 0.27 |
| Interest | 0.5 | 0.61 | 0.43 | 0.71 |
| Depreciation | 0.34 | 0.34 | 0.34 | 0.35 |
| PBT | 2.95 | 6.03 | 5.22 | 4.35 |
| Tax % | 25.42% | 33.67% | 19.35% | 37.7% |
| Net Profit | 2.2 | 4 | 4.21 | 2.71 |
| EPS in Rs | 44 | 6.74 | 7.09 | 3.35 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 23.7 | 35.21 | 35.13 | 49.13 | 60.63 |
| Expenses | 20.12 | 31.95 | 26.74 | 39.59 | 49.5 |
| Operating Profit | 3.58 | 3.26 | 8.39 | 9.54 | 11.13 |
| OPM % | 15.11% | 9.26% | 23.88% | 19.42% | 18.36% |
| Other Income | 0.02 | 0.34 | 0.31 | 0.51 | 0.27 |
| Interest | 1.62 | 1.33 | 0.85 | 1.11 | 1.14 |
| Depreciation | 0.75 | 0.73 | 0.68 | 0.67 | 0.7 |
| PBT | 1.23 | 1.54 | 7.17 | 8.27 | 9.56 |
| Tax % | 59.35% | 20.13% | 32.22% | 26.24% | 27.62% |
| Net Profit | 0.49 | 1.23 | 4.87 | 6.11 | 6.92 |
| EPS in Rs | 9.8 | 24.6 | 97.4 | 10.3 | 8.56 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.5 | 0.5 | 0.5 | 5.93 | 8.08 |
| Reserves | -1.4 | -0.18 | 5.37 | 10.29 | 39.27 |
| Borrowings | 17.62 | 16.19 | 17.09 | 15.61 | 21.59 |
| Other Liabilities | 10.68 | 13.16 | 10.91 | 10.7 | 12.58 |
| Total Liabilities | 27.4 | 29.67 | 33.87 | 42.53 | 81.52 |
| Fixed Assets | 12.33 | 12.2 | 11.59 | 10.99 | 10.77 |
| CWIP | 0 | 0 | 0 | 0.02 | 1.33 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 15.06 | 17.46 | 22.27 | 31.51 | 69.41 |
| Total Assets | 27.4 | 29.67 | 33.87 | 42.53 | 81.52 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 4.95 | 3.35 | 0.28 | -1.76 | -16.42 |
| Investing | -0.37 | -0.55 | -0.06 | -0.02 | -1.59 |
| Financing | -4.58 | -2.76 | 0.05 | 1.67 | 20.87 |
| Net Cash Flow | -0.01 | 0.04 | 0.27 | -0.11 | 2.86 |
| Free Cash Flow | 4.56 | 2.77 | 0.21 | -1.85 | -18.22 |
| CFO/OP | 138 | 103 | 3 | -2 | -127 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 96.1 | 98.17 | 105 | 55.87 | 67.55 |
| Inventory Days | 208 | 115 | 273 | 347 | 297 |
| Days Payable | 360 | 263 | 210 | 112 | 71.22 |
| Cash Conversion Cycle | -55.01 | -49.58 | 168 | 291 | 293 |
| Working Capital Days | -16.02 | -20.84 | 36.26 | 99.63 | 232 |
| ROCE % | — | 17.21% | 40.64% | 34.24% | 21.25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Curis Lifesciences insights
34 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Copy of Newspaper Publication
8 Sep - Curis Lifesciences will hold its 10th AGM on 29 September 2026 via VC/OAVM; remote e-voting details published. 8 Sep - Curis Lifesciences will hold its 10th AGM on 29 September 2026 via VC/OAVM; remote e-voting details published.
2
Outcome of Board Meeting
7 Sep - Board approved FY26 Director’s Report, AGM notice, related party transactions; 10th AGM on 29 September 2026. 7 Sep - Board approved FY26 Director’s Report, AGM notice, related party transactions; 10th AGM on 29 September 2026.
3
Shareholders meeting
7 Sep - 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted. 7 Sep - 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted.
4
Cessation
3 Sep - Company Secretary and Compliance Officer Nikhil Purohit resigned effective 3 September 2026. 3 Sep - Company Secretary and Compliance Officer Nikhil Purohit resigned effective 3 September 2026.
5
Resignation of Director/KMP/SMP
3 Sep - Curis Lifesciences Limited has informed about Resignation of Director/KMP/SMP 3 Sep - Curis Lifesciences Limited has informed about Resignation of Director/KMP/SMP
Frequently Asked Questions about Curis Lifesciences
What does Curis Lifesciences Ltd do?
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
Where is Curis Lifesciences Ltd (CURIS) listed?
Curis Lifesciences Ltd trades as CURIS on the NSE.
Which sector does Curis Lifesciences Ltd belong to?
Curis Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Curis Lifesciences Ltd?
Curis Lifesciences Ltd has a market capitalisation of ₹160.35 Cr, which places it in the Small Cap band.
What is the PE ratio of Curis Lifesciences Ltd?
Curis Lifesciences Ltd trades at a PE ratio of 24.40, against a book value of ₹58.57 per share.
What is the 52-week high and low of Curis Lifesciences Ltd?
Over the last 52 weeks Curis Lifesciences Ltd has traded between ₹83.6 and ₹228.8.
What is the Return on Equity (ROE) of Curis Lifesciences Ltd?
Curis Lifesciences Ltd reported a return on equity of 37.62%. Its debt-to-equity ratio is 0.46.
Company Information
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CURIS.md for Curis Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.